Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from Needham & Company LLC

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports. They presently have a $2.50 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 138.10% from the stock’s previous close.

LUCD has been the topic of several other reports. Ascendiant Capital Markets lowered their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research report on Tuesday, September 10th. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Tuesday, August 13th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Buy” and an average price target of $3.94.

Lucid Diagnostics Price Performance

Shares of Lucid Diagnostics stock opened at $1.05 on Thursday. The firm has a market cap of $56.69 million, a price-to-earnings ratio of -0.85 and a beta of 1.41. The stock has a 50-day simple moving average of $0.86 and a 200-day simple moving average of $0.85. Lucid Diagnostics has a 52-week low of $0.63 and a 52-week high of $1.58.

Lucid Diagnostics (NASDAQ:LUCD) last posted its earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.98 million for the quarter. As a group, equities research analysts predict that Lucid Diagnostics will post -0.82 earnings per share for the current year.

Institutional Trading of Lucid Diagnostics

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC raised its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the quarter. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.